ACE inhibitors may be linked to increased risk of Alzheimer’s disease (AD) and frontotemporal dementia [33] while CCBs may be associated with a lower risk of AD [34]. This evidence concerns the gene ACE and early-onset autosomal dominant Alzheimer disease.